CVS Plunges to $3.99B Loss on Massive Goodwill Impairment

Ticker: CVS · Form: 10-Q · Filed: 2025-10-29T00:00:00.000Z

Sentiment: bearish

Topics: Goodwill Impairment, Net Loss, Healthcare Services, Pharmacy Benefits Management, Retail Pharmacy, Aetna, Q3 Earnings

Related Tickers: CVS, UNH, CI, ELV

TL;DR

**CVS's $5.7B goodwill impairment is a red flag; sell on this massive earnings miss.**

AI Summary

CVS Health Corporation reported a significant net loss of $3.99 billion for the three months ended September 30, 2025, a stark contrast to the net income of $71 million in the prior-year period. This substantial loss was primarily driven by a goodwill impairment charge of $5.725 billion. Total revenues increased by 7.8% to $102.871 billion for the quarter, up from $95.428 billion, fueled by growth in product sales and premiums. However, operating income swung to a loss of $3.207 billion from a gain of $832 million in the same quarter last year. For the nine months ended September 30, 2025, the company recorded a net loss of $1.195 billion, compared to a net income of $2.963 billion in the corresponding 2024 period. Despite the net loss, cash provided by operating activities remained strong at $7.249 billion for the nine months, consistent with $7.247 billion in the prior year. The company is exiting individual public health insurance exchanges in states where Aetna operates, effective January 2026, and continues to expand its health services through acquisitions like Signify Health and Oak Street Health.

Why It Matters

This significant net loss, primarily due to a $5.725 billion goodwill impairment, signals potential challenges in CVS Health's acquisition strategy and valuation of its acquired assets, particularly within its Health Services segment. For investors, this raises questions about future profitability and the long-term value of recent acquisitions like Signify Health and Oak Street Health, potentially impacting stock performance. Employees might face uncertainty if the impairment indicates underperforming segments, while customers could see shifts in service offerings as the company re-evaluates its portfolio, such as the exit from individual public health insurance exchanges. In the competitive healthcare market, this impairment could weaken CVS's position against rivals like UnitedHealth Group and Cigna, who are also aggressively expanding integrated care models.

Risk Assessment

Risk Level: high — The company reported a net loss of $3.99 billion for the three months ended September 30, 2025, primarily due to a $5.725 billion goodwill impairment charge. This substantial impairment indicates that the carrying value of certain assets, likely from recent acquisitions, exceeds their fair value, signaling potential overpayment or underperformance. Additionally, the operating income swung from a gain of $832 million in Q3 2024 to a loss of $3.207 billion in Q3 2025, directly reflecting this significant write-down.

Analyst Insight

Investors should carefully re-evaluate CVS Health's long-term growth strategy, particularly its recent acquisitions in the Health Services segment, given the $5.725 billion goodwill impairment. Consider reducing exposure or holding off on new investments until management provides a clear path to profitability and demonstrates the value realization from these integrated care initiatives. Monitor future filings for further impairments or strategic shifts.

Financial Highlights

revenue
$102.871B
operating Margin
-3.1%
net Income
($3.99B)
eps
($3.13)
revenue Growth
+7.8%

Revenue Breakdown

SegmentRevenueGrowth
Products$64,590M+8.1%
Premiums$33,719M+8.7%
Services$3,930M-8.2%
Net investment income$632M+14.9%

Key Numbers

Key Players & Entities

FAQ

Why did CVS Health report a net loss in Q3 2025?

CVS Health reported a net loss of $3.99 billion for the three months ended September 30, 2025, primarily due to a significant goodwill impairment charge of $5.725 billion. This charge negatively impacted operating income, which swung to a loss of $3.207 billion from a gain of $832 million in the prior year.

What was CVS Health's revenue performance in the third quarter of 2025?

CVS Health's total revenues increased by 7.8% to $102.871 billion for the three months ended September 30, 2025, up from $95.428 billion in the same period of 2024. This growth was driven by increases in product sales and premiums.

How did the goodwill impairment impact CVS Health's balance sheet?

The goodwill impairment charge of $5.725 billion directly reduced the goodwill asset on CVS Health's balance sheet, which decreased from $91.272 billion at December 31, 2024, to $85.478 billion at September 30, 2025. This also contributed to a decrease in total CVS Health shareholders' equity from $75.560 billion to $72.928 billion.

What are CVS Health's strategic changes in its Health Care Benefits segment?

CVS Health plans to exit the states in which its Aetna operations participate on the individual public health insurance exchanges, effective January 2026. This indicates a strategic shift in its health insurance product offerings.

What acquisitions are part of CVS Health's Health Services segment?

The Health Services segment includes Signify Health, Inc., a leader in health risk assessments and value-based care, and Oak Street Health, Inc., a multi-payor operator of value-based primary care centers serving Medicare eligible patients. These acquisitions are key to CVS Health's expansion into health care delivery.

What is the significance of the $5.725 billion goodwill impairment for investors?

For investors, the $5.725 billion goodwill impairment suggests that the fair value of certain acquired assets, likely within the Health Services segment, is now less than their carrying value. This could signal overvaluation at the time of acquisition or underperformance, potentially impacting future earnings and the company's stock price.

How has CVS Health's cash flow from operations performed?

Despite the net loss, CVS Health's net cash provided by operating activities remained strong and stable, totaling $7.249 billion for the nine months ended September 30, 2025, which is consistent with $7.247 billion in the corresponding period of 2024.

What is CVS Health's current number of retail locations?

As of September 30, 2025, CVS Health's Pharmacy & Consumer Wellness segment operated approximately 9,000 retail locations, in addition to online retail pharmacy websites, specialty pharmacy stores, compounding pharmacies, and infusion services branches.

What are the primary risks highlighted by the Q3 2025 filing for CVS Health?

The primary risk highlighted is the $5.725 billion goodwill impairment, indicating potential issues with asset valuation or the performance of acquired businesses. This could lead to further write-downs or impact the company's ability to generate expected returns from its strategic investments.

What is the role of Cordavis TM within CVS Health?

Cordavis TM is a subsidiary within CVS Health's Health Services segment that works directly with pharmaceutical manufacturers to commercialize and/or co-produce high-quality biosimilar products. This initiative aims to create new sources of value and potentially lower healthcare costs.

Risk Factors

Industry Context

The healthcare industry is characterized by intense competition across various segments, including retail pharmacy, PBM services, and health insurance. Trends include increasing consolidation, a growing focus on value-based care, and significant regulatory oversight. Companies are investing heavily in technology and expanding into health services to capture more of the healthcare dollar.

Regulatory Implications

CVS Health faces significant regulatory scrutiny in its pharmacy, PBM, and insurance operations. Changes in government reimbursement policies, drug pricing regulations, and healthcare reform initiatives pose ongoing risks. The company's exit from certain insurance exchanges highlights the challenges of navigating these complex regulatory landscapes.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Goodwill impairment
A charge taken when the carrying value of goodwill on a company's balance sheet is deemed to be irrecoverable, indicating that the acquired business is not performing as expected. (The primary driver of the significant net loss in Q3 2025, totaling $5.725 billion.)
Operating income (loss)
A measure of a company's profit after deducting operating expenses from revenues, before accounting for interest and taxes. (Swung to a loss of $3.207 billion in Q3 2025 from a gain of $832 million in Q3 2024, highlighting operational challenges.)
Net investment income
Income generated from a company's investments, such as interest earned on bonds or dividends from stocks. (Showed an increase of 14.9% in Q3 2025, benefiting from higher interest rates.)
Noncontrolling interests
The portion of equity interest in a subsidiary that is not attributable to the parent company. (Represents a small portion of the net loss, with $15 million in Q3 2025.)
Weighted average shares outstanding
The average number of a company's shares outstanding over a period, used to calculate earnings per share. (Basic shares outstanding were 1,269 million in Q3 2025, with diluted shares also at 1,269 million.)

Year-Over-Year Comparison

Compared to the prior year, CVS Health experienced a dramatic shift from net income to a significant net loss in Q3 2025, primarily due to a $5.725 billion goodwill impairment. While total revenues saw a healthy 7.8% increase to $102.871 billion, operating income swung to a substantial loss. However, cash flow from operations remained robust and consistent year-over-year, indicating underlying operational cash generation strength despite the reported net loss.

Filing Stats: 4,717 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-10-29 06:34:58

Key Financial Figures

Filing Documents

Financial Information

Part I Financial Information

Financial Statements

Item 1. Financial Statements 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 48

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 73

Controls and Procedures

Item 4. Controls and Procedures 73

Other Information

Part II Other Information

Legal Proceedings

Item 1. Legal Proceedings 74

Risk Factors

Item 1A. Risk Factors 74

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 74

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 74

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 74

Other Information

Item 5. Other Information 74

Exhibits

Item 6. Exhibits 75

Signatures

Signatures 76 Form 10-Q Table of Contents

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements Index to Condensed Consolidated Financial Statements Page Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Shareholders' Equity (Unaudited) for the three months ended September 30, 2025 and 2024, the three months ended June 30, 2025 and 2024 and the three months ended March 31, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 9 Report of Independent Registered Public Accounting Firm 47 1 Index to Condensed Consolidated Financial Statements CVS Health Corporation Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, In millions, except per share amounts 2025 2024 2025 2024 Revenues: Products $ 64,590 $ 59,674 $ 182,866 $ 169,610 Premiums 33,719 30,925 100,734 91,983 Services 3,930 4,279 11,135 12,108 Net investment income 632 550 1,639 1,398 Total revenues 102,871 95,428 296,374 275,099 Operating costs: Cost of products sold 57,045 52,948 162,107 151,019 Health care costs 32,020 29,922 92,472 85,578 Operating expenses 11,288 10,557 33,522 31,185 Goodwill impairment 5,725 — 5,725 — Restructuring charges — 1,169 — 1,169 Total operating costs 106,078 94,596 293,826 268,951 Operating income (loss) ( 3,207 ) 832 2,548 6,148 Gain on deconsolidation of subsidiary 483 — 483 — Interest expense ( 784 ) ( 752 ) ( 2,332 ) ( 2,200 ) Other income 26 25 83 74 Income (loss) before income tax provision ( 3,482 ) 105 782 4,022 Income tax p

View on Read The Filing